Table 1.
Demographics and Baseline Characteristics
| LT4-supplemented (n = 30) | Placebo (n = 29) | |
|---|---|---|
| Infants less than 28 weeks' gestation randomized | 75 | 78 |
| Sex (males) | 44 (59%) | 45 (58%) |
| Birth weight (g) | 820.7 (183.9) | 842.2 (200.0) |
| Gestational age (weeks) | 25.8 (1.3) | 25.8 (1.4) |
| CRIB score | 5.7 (3.5) | 5.4 (4.1) |
| No. of twin births (pairs) | 4 (5.3%) | 6 (7.7%) |
| Infant baseline fT4 (pmol/L) | 12.2 (6.9) | 10.5 (6.3) |
| Infant baseline leg length (mm) | 38.7 (7.1) | 39.54 (6.8) |
| Maternal age (years) | 28.8 (5.8) | 28.9 (5.8) |
| Died | 7 | 9 |
| Unable to contact | 24 | 18 |
| Mis-labeled assessment | 0 | 1 |
| Cohort assessed by Bayley's III mental and psychomotor developmental indices at 42 months | 30 | 29 |
| Cohort assessed by subarachnoid space width at 36 weeks | 61 | 57 |
Data are expressed as mean (SD) for continuous outcomes and n (%) for dichotomous variables.
CRIB, clinical risk index for babies; fT4, free thyroxine; LT4, levothyroxine; SD, standard deviation.